TACC3 and urothelial carcinoma: A phase Ib trial of BGJ398 in combination with BYL719 (PI3K inhibitor) on solid tumors showed encouraging results as eight patients over 24 showed a partial response, among them, one patient with a urothelial carcinoma bearing FGFR3‐TACC3 had a complete tumor shrinkage for 4 months (NCT01928459).